Spironolactone does not prevent restenosis after coronary stenting in humans

Annals of the Academy of Medicine Singapore

Volumn 33, Issue 6, 2004, Pages 769-774

  Kursaklioglu, Hurkan ^a   Iyisoy, A ^a   Amasyali, B ^a   Celik, T ^a   Ozturk, C ^a   Kose, S ^a   Isik, E ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

Angiography; Coronary lesion; In stent restenosis; Neointimal proliferation

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEPARIN; PLACEBO; SPIRONOLACTONE;

ADULT; ANGIOCARDIOGRAPHY; ARTERY DIAMETER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; INTIMA; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; SIDE EFFECT;

EID: 13244274926     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Forrester JS, Fishbein M, Helfant R, Fagin J. A paradigm for restenosis based on cell biology: clues for the development of new preventive therapies. J Am Coll Cardiol 1991;17:758-69.
2. Holmes DR Jr, Vlietstra RE, Smith HC, Vetrovec GW, Kent KM, Cowley MJ, et al. Restenosis after percutaneous transluminal coronary angioplasty (PTCA): a report from the PTCA registry of the National Heart, Lung, and Blood Institute. Am J Cardiol 1984;53:77-C81
3. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, et al. A comparison of balloon-expandable stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994;31:489-95.
4. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I. A randomised comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994;331:496-501.
5. Mintz GS, Hoffmann R, Mehran R, Pichard AD, Kent KM, Satler LF, et al. In-stent restenosis: The Washington Hospital Center experience. Am J Cardiol 1998;81(Suppl)7A:7-13E.
6. Libby P, Schwartz D, Brogi E, Tanaka H, Clinton SK. A cascade model for restenosis. A special case of atherosclerosis progression. Circulation 1992;86(Suppl):III47-52.
7. Liu MW, Roubin GS, King SB 3rd. Restenosis after coronary angioplasty: potential biologic determinants and roleof intimal hyperplasia. Circulation 1989;79:1374-87.
8. Desmet W, Vrolix M, De Scheeder I, Van Lierde J, Willems JL, Piessens J. Angiotensin-converting enzyme inhibition with fosinopril sodium in the prevention of restenosis after coronary angioplasty. Circulation 1994;89:385-92.
9. Weintraub WS, Boccuzzi SJ, Klein JL, Kosinski AS, King SB 3rd, Ivanhoe R, et al. Lack of effect of lovastatin on restenosis after coronary angioplasty. N Engl J Med 1994;331:1331-7.
10. Leaf A, Jorgensen MB, Jacobs AK, Cote G, Schoenfeld DA, Scheer J, et al. Do fish oils prevent restenosis after coronary angioplasty? Circulation 1994;90:2248-57.
11. Pepine CJ, Hirshfeld JW, Macdonald RG, Henderson MA, Bass TA, Goldberg S, et al. A controlled trial of corticosteroids to prevent restenosis after coronary angioplasty. Circulation 1990;81:1753-61.
12. Keefe JH Jr, McCallister BD, Bateman TM, Kuhnlein DL, Ligon RW, Hartzler GO. Ineffectiveness of colchicine for the prevention of restenosis after coronary angioplasty. J Am Coll Cardiol 1992;19:1597-600.
13. Hermans WR, Rensing BJ, Strauss BH, Serruys PW. Prevention of restenosis after percutaneous transluminal coronary angioplasty: the search for a "magic bullet". Am Heart J 1991;122:171-87.
14. Powell JS, Clozel JP, Muller RK, Kuhn H, Hefti F, Hosang M, et al. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 1989;245:186-8.
15. Van Belle E, Bauters C, Wernert N, Delcayre C, Piraube C, Dupuis B, et al. Reduction of neointimal hyperplasia with perindopril after experimental angioplasty is associated with inhibition of the c-jun and c-fos oncogenes. J Am Coll Cardiol 1994;23 (Abstract suppl)395A.
16. Faxon DP. Effect of high dose angiotensin-converting enzyme inhibition on restenosis: final results of the MARCATOR Study, a multicenter, double-blind, placebo-controlled trial of cilazapril. J Am Coll Cardiol 1995;2:362-9.
17. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 1991;14:1849-65.
18. Campbell-Boswell M, Robertson AL Jr. Effects of angiotensin II and vasopressin on human smooth muscle cells in vitro. Exp Mol Pathol 1981;35:265-76.
19. Blaes N, Boissel JP. Growth-stimulating effect of catecholamines on rat aortic smooth muscle cells in culture. J Cell Physiol 1983;116:167-72.
20. Nakaki T, Nakayama M, Yamamoto S, Kato R. Alpha-1 adrenergic stimulation and beta-2 adrenergic inhibition of DNA synthesis invascular smooth muscle cells. Mol Pharmacol 1990;27:30-6.
21. Van Belle E, Bauters C, Wernert N, Hamon M, McFadden EP, Racadot A, et al. Neointimal thickening after balloon denudation is enhanced by aldosterone and inhibited by spironolactone, and aldosterone antagonist. Cardiovasc Res 1995;29:27-32.
22. Antoniucci D, Valenti R, Santora GM, Bolognese L, Trapani M, Cerisano G, et al. Restenosis after coronary stenting in current clinical practice. Am Heart J 1998;35:510-8.
23. Meyer WJ 3rd, Nichols NR. Mineralocorticoid binding in cultured smooth muscle cells and fibroblasts from rat aorta. J Steroid Biochem 1981;14:1157-68.
24. Lombes M, Oblin ME, Gasc JM, Baulieu EE, Farman N, Bonvalet JP. Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor. Circ Res 1992;71:503-10.
25. Mikami H, Ogihara T, Ohde H, Katahira K, Kohara K, Kumahara Y. Direct vascular effects of 19-hydroxyandrostenedione. Methods Find Exp Clin Pharmacol 1989;11:241-8.
26. Purdy RE, Weber MA, Drayer JI. Vasoconstrictor effects of aldosterone in isolated vascular tissue. Clin Exp Hypertens A 1982;4:1583-91.
27. Couture R, Regoli D. Vascular reactivity to angiotensin and noradrenaline in rats maintained on a sodium free diet or made hypertensive with desoxycorticosterone acetate and salt (DOCA/salt). Clin Exp Hypertens 1980;2:25-43.
28. Bockman CS, Jeffries WB, Pettinger WA, Abel PW. Enhanced release of endothelium-derived relaxing factor in mineralocorticoid hypertension. Hypertension 1992;20:304-13.
29. Ward MR, Kanellakis P, Ramsey D, Funder J, Bobik A. Eplerenone suppresses constrictive remodeling and collagen accumulation after angioplasty in porcine coronary arteries. Circulation 2001;104:467-72.
30. Kuntz RE, Gibson CM, Nobuyoshi M, Baim DS. Generalized model of restenosis after conventional balloon angioplasty, stenting and directional atherectomy. J Am Coll Cardiol 1993;21:15-25.
31. Clemmons DR. Interaction of circulating cell-derived and plasma growth factors in stimulating cultured smooth muscle cell replication. J Cell Physiol 1984;121:425-30.
32. Libby P, Edelman E. Restenosis: Involvement of growth factors and cytokines. In: Topol EJ, editor. Textbook of Interventional Cardiology. Philadelphia: WB Saunders Co, 1999:346-57.
33. Schwartz RS, Huber KC, Murphy JG, Edwards WD, Camrud AR, Vlietstra RE, et al. Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. J Am Coll Cardiol 1992;19:267-74.
34. Schwartz RS. Animal models of human coronary restenosis. In: Topol EJ, editor. Textbook of Interventional Cardiology. Philadelphia: WB Saunders Co, 1999:358-78.